Cellebrite DI (NASDAQ:CLBT) PT Raised to $17.00 at Lake Street Capital

Cellebrite DI (NASDAQ:CLBT) had its price objective lifted by Lake Street Capital from $13.50 to $17.00 in a research report released on Friday morning, Benzinga reports. The firm currently has a buy rating on the stock.

CLBT has been the topic of several other reports. Craig Hallum increased their price objective on shares of Cellebrite DI from $16.00 to $20.00 and gave the company a buy rating in a report on Friday. JPMorgan Chase & Co. upped their price target on shares of Cellebrite DI from $14.00 to $15.00 and gave the stock an overweight rating in a research report on Wednesday, August 14th. Finally, Needham & Company LLC lifted their price objective on Cellebrite DI from $14.00 to $17.00 and gave the stock a buy rating in a report on Friday. Seven analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, Cellebrite DI presently has a consensus rating of Buy and a consensus price target of $17.33.

Cellebrite DI Stock Down 0.4 %

Shares of Cellebrite DI stock opened at $16.37 on Friday. The firm has a market cap of $3.37 billion, a PE ratio of -28.22, a P/E/G ratio of 1.90 and a beta of 1.50. Cellebrite DI has a twelve month low of $6.36 and a twelve month high of $16.89. The business has a 50-day moving average price of $12.75 and a 200 day moving average price of $11.63.

Cellebrite DI (NASDAQ:CLBT) last issued its quarterly earnings data on Thursday, August 15th. The company reported $0.10 EPS for the quarter, beating the consensus estimate of $0.08 by $0.02. The company had revenue of $95.70 million for the quarter, compared to analyst estimates of $91.94 million. Cellebrite DI had a positive return on equity of 417.94% and a negative net margin of 32.57%. Cellebrite DI’s quarterly revenue was up 24.8% compared to the same quarter last year. During the same period last year, the company earned $0.05 earnings per share. On average, sell-side analysts expect that Cellebrite DI will post 0.34 EPS for the current year.

Institutional Trading of Cellebrite DI

Several large investors have recently bought and sold shares of the business. Point72 Asia Singapore Pte. Ltd. boosted its holdings in shares of Cellebrite DI by 59.6% during the 2nd quarter. Point72 Asia Singapore Pte. Ltd. now owns 2,724 shares of the company’s stock worth $33,000 after purchasing an additional 1,017 shares during the last quarter. Parallel Advisors LLC grew its holdings in Cellebrite DI by 75.0% in the 4th quarter. Parallel Advisors LLC now owns 3,500 shares of the company’s stock valued at $30,000 after buying an additional 1,500 shares in the last quarter. Quarry LP acquired a new stake in shares of Cellebrite DI in the 4th quarter worth $36,000. California State Teachers Retirement System boosted its position in shares of Cellebrite DI by 9.1% during the 1st quarter. California State Teachers Retirement System now owns 56,953 shares of the company’s stock valued at $631,000 after acquiring an additional 4,734 shares during the last quarter. Finally, Lazard Asset Management LLC grew its holdings in shares of Cellebrite DI by 28.7% in the first quarter. Lazard Asset Management LLC now owns 21,697 shares of the company’s stock valued at $240,000 after purchasing an additional 4,842 shares during the period. Hedge funds and other institutional investors own 45.88% of the company’s stock.

About Cellebrite DI

Cellebrite DI Ltd. develops solutions for legally sanctioned investigations in Europe, the Middle East, Africa, the Americas, and the Asia-Pacific. The company's DI suite of solutions allows users to collect, review, analyze, and manage digital data across the investigative lifecycle with respect to legally sanctioned investigations used in various cases, including child exploitation, homicide, anti-terror, border control, sexual crimes, human trafficking, corporate security, cryptocurrency, and intellectual property theft.